Article

Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval

2019-01-08

Abstract excerpt

1 Despite strong vetting for disease activity, only 10% of candidate new molecular entities in early stage clinical trials are eventually approved. Analyzing historical pipeline data, Nelson et al. 2015 (Nat. Genet.) concluded pipeline drug targets with human genetic evidence of disease association are twice as likely to lead to approved drugs. Taking advantage of recent clinical development advances and rapid gro...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: aa134dc2-449c-5322-b4be-01feb09d8b01
DOI: 10.1101/513945

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approvalDOI 10.1101/513945Read

Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval.Semantic proximity Read

Refining the impact of genetic evidence on clinical successSemantic proximity Read

Refining the impact of genetic evidence on clinical success.Semantic proximity Read

The support of human genetic evidence for approved drug indications.Semantic proximity Read

Retrospective evaluation of human genetic evidence for clinical trial success using Mendelian randomization and machine learningSemantic proximity Read

The impact on clinical success from the 23andMe cohortSemantic proximity Read

Impact of proteogenomic evidence on clinical successSemantic proximity Read

Integration of genetic evidence to identify approved drug targetsSemantic proximity Read

Leveraging Large-Scale Biobanks for Therapeutic Target DiscoverySemantic proximity Read

Multi-layered genetic approaches to identify approved drug targetsSemantic proximity Read

Network and pathway expansion of genetic disease associations identifies successful drug targetsSemantic proximity Read

Pathway analysis of GWAS loci identifies novel drug targets and repurposing opportunitiesSemantic proximity Read